Statins: Promising Protective Shield against Doxorubicin Cardiotoxicity
نویسندگان
چکیده
منابع مشابه
Frederine, a new and promising protector against doxorubicin-induced cardiotoxicity.
The flavonoid 7-monohydroxyethylrutoside (monoHER) can protect against doxorubicin-induced cardiotoxicity. A drawback of monoHER therapy would be the relatively high dose needed to obtain complete protection (500 mg/kg in mice). Therefore, we synthesized a series of new compounds with improved antioxidant properties. After characterization of antioxidant activity, cardioprotection in vitro, and...
متن کاملIn Vivo Protective Effects of Diosgenin against Doxorubicin-Induced Cardiotoxicity
Doxorubicin (DOX) induces oxidative stress leading to cardiotoxicity. Diosgenin, a steroidal saponin of Dioscorea opposita, has been reported to have antioxidant activity. Our study was aimed to find out the protective effect of diosgenin against DOX-induced cardiotoxicity in mice. DOX treatment led to a significant decrease in the ratio of heart weight to body weight, and increases in the bloo...
متن کاملProtective Effects of Lycopene and Tomato Extract Against Doxorubicin-Induced Cardiotoxicity
The protective effect of tomato extract and lycopene on acute doxorubicin-induced myocardial toxicity was evaluated in mice. Doxorubicin toxicity, induced by a single intraperitoneal injection (15 mg/kg), was revealed by elevated serum CPKMB and histopathological observations. Tomato extract (1.2 and 2.4 g/kg, i.p.) and lycopene (1.7 and 3.5 mg/kg, i.p.), prevented the rise in serum CPKM...
متن کاملPrevention from Doxorubicin Cardiotoxicity by Available Protective Agents in Iran
Doxorubicin, used in pediatric chemotherapy regimens, has cardiotoxic effects. Dexrazoxane is co-administrated with doxorubicin to prevent its cardiotoxicity. Here we have explored some alternative food or drugs to be used in absence of dexrazoxane since it’s not readily available in Iran at this time. Keywords: Pediatric, chemotherapy, doxorubicin, cardiotoxicity, dexrazoxane, Iran.
متن کاملCan ErbB2 overexpression protect against doxorubicin cardiotoxicity?
IDENTIFICATION OF THE human epidermal growth factor receptor (HER2/ErbB2) as a target for therapy in HER2/ErbB2-positive breast cancer was a huge milestone in treatment of these typically highly aggressive cancers. At 8-yr follow-up, trastuzumab, a monoclonal antibody against HER2/ErbB2, increased survival by 40% compared with standard chemotherapy: anthracycline (doxorubicin), cyclophosphamide...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Cardiology & Cardiovascular Therapy
سال: 2017
ISSN: 2474-7580
DOI: 10.19080/jocct.2017.07.555710